Overexpression of OCT4 is associated with gefitinib resistance in non-small cell lung cancer

Bin Li; Zhouhong Yao; Yunyan Wan; Dianjie Lin

doi:10.18632/oncotarget.12999

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Overexpression of OCT4 is associated with gefitinib resistance in non-small cell lung cancer

Bin Li, Zhouhong Yao, Yunyan Wan and Dianjie Lin _

PDF | HTML | How to cite

Oncotarget. 2016; 7:77342-77347. https://doi.org/10.18632/oncotarget.12999

Metrics: PDF 1577 views | HTML 1695 views | ?

Abstract

Bin Li1, Zhouhong Yao1, Yunyan Wan1, Dianjie Lin1

1Department of Respiratory Medicine, Shandong Provincial Hospital Affiliated to Shandong University, Shandong University, Jinan, Shandong, China, 250021

Correspondence to:

Dianjie Lin, email: [email protected]

Keywords: NSCLC, chemoresistance, OCT4, gefitinib, proliferation, apoptosis

Received: August 15, 2016 Accepted: October 14, 2016 Published: October 31, 2016

ABSTRACT

Epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors (TKIs) have emerged as first-line drugs for non-small cell lung cancers (NSCLCs). However, the resistance to TKIs represents the key limitation for their therapeutic efficacy. We found that the difference of OCT4 expression between NSCLC and the adjacent non-tumourous tissues was statistically significant. Knockdown of OCT4 in NSCLC cells could decrease cell proliferation, and potentiate apoptosis induced by gefitinib, suggesting OCT4 may contribute to gefitinib resistance in NSCLC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12999

Publication Alerts

Research Papers:

Overexpression of OCT4 is associated with gefitinib resistance in non-small cell lung cancer

Abstract